AxoGen is a biotech company developing treatment options for the reconstruction and repair of peripheral nerve injuries. It is passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.
AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. 

Type
Public
HQ
Alachua, US
Founded
2002
Size (employees)
114 (est)+41%
AxoGen was founded in 2002 and is headquartered in Alachua, US

Key People/Management at AxoGen

Karen Zaderej

Karen Zaderej

CEO
Gregory G. Freitag

Gregory G. Freitag

General Counsel, SVP Business Development, Director

AxoGen Office Locations

AxoGen has an office in Alachua
Alachua, US (HQ)
13631 Progress Blvd

AxoGen Financials and Metrics

AxoGen Financials

AxoGen's revenue was reported to be $12.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

12.2 m

Gross profit (Q1, 2017)

10.3 m

Gross profit margin (Q1, 2017), %

84%

Net income (Q1, 2017)

(3.8 m)

EBIT (Q1, 2017)

(3.2 m)

Market capitalization (19-Oct-2017)

659.2 m

Cash (31-Mar-2017)

25.9 m
AxoGen's current market capitalization is $659.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

10.9 m16.8 m27.3 m41.1 m

Revenue growth, %

54%63%50%

Cost of goods sold

2.4 m3.4 m4.8 m6.5 m

Gross profit

8.5 m13.4 m22.5 m34.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.2 m4.7 m5 m6.4 m8.2 m8.1 m10.4 m11.2 m12.2 m

Cost of goods sold

887.8 k896.2 k982.9 k1 m1.4 m1.4 m1.5 m1.7 m1.9 m

Gross profit

3.3 m3.8 m4 m5.4 m6.7 m6.7 m8.8 m9.5 m10.3 m

Gross profit Margin, %

79%81%80%84%83%83%85%85%84%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.1 m8.2 m25.9 m30 m

Accounts Receivable

1.2 b

Inventories

3.4 m3.2 m3.9 m5.5 m

Current Assets

25.7 m14.4 m35.1 m44 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

14.2 m11.8 m19.3 m15.6 m29.9 m20.9 m18.3 m16 m25.9 m

Inventories

3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m

Current Assets

20.3 m18 m26 m23.2 m38.6 m31.5 m29.7 m28.7 m40.9 m

PP&E

597.3 k613.2 k583.4 k663.9 k830.1 k1.3 m1.3 m1.3 m1.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(14.6 m)(17.7 m)(13.4 m)(14.4 m)

Depreciation and Amortization

138.3 k198.9 k249 k

Accounts Receivable

(902.2 k)(1 m)(2 m)

Inventories

(247.3 k)184.8 k(720.3 k)5.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.7 m)(3.2 m)(3.6 m)(3.2 m)(3 m)(3.7 m)(2.8 m)(2.3 m)(3.8 m)

Inventories

3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m

Accounts Payable

2.2 m2 m3.4 m3.4 m4.1 m3.8 m3.9 m4.6 m6.7 m
Y, 2017

Financial Leverage

3.6 x
Show all financial metrics

AxoGen Market Value History

Traffic Overview of AxoGen

AxoGen Online and Social Media Presence

AxoGen Company Life and Culture

You may also be interested in